Anti-tumor activity of metformin: From metabolic and epigenetic perspectives

Oncotarget

Volumn 8, Issue 3, 2017, Pages 5619-5628

  Yu, Xilan ^a   Mao, Wuxiang ^a   Zhai, Yansheng ^a   Tong, Chong ^a   Liu, Min ^a   Ma, Lixin ^a   Yu, Xiaolan ^a   Li, Shanshan ^a  

^a HUBEI UNIVERSITY   (China)

Author keywords

Epigenetic modifications; Metabolism; Metformin; Therapeutic targets

Indexed keywords

CYANOCOBALAMIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H2B; HISTONE H2BK120; HISTONE METHYLTRANSFERASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN P53; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN B; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CELL METABOLISM; CITRIC ACID CYCLE; DIET RESTRICTION; DNA METHYLATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETIC MODIFICATION; EPIGENETICS; GENETIC REGULATION; GLYCOLYSIS; HISTONE UBIQUITINATION; HUMAN; LISTERIA MONOCYTOGENES; LIVER CELL CARCINOMA; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATIC CANCER CELL LINE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; GENETIC EPIGENESIS; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; EPIGENESIS, GENETIC; HUMANS; METFORMIN; NEOPLASMS;

EID: 85011994118     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13639     Document Type: Review

References (60)

1. Leone A, Di Gennaro E, Bruzzese F, Avallone A and Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer treatment and research. 2014; 159:355-376.
2. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO and de Vries EG. Metformin: taking away the candy for cancer? European journal of cancer. 2010; 46:2369-2380.
3. Dowling RJ, Goodwin PJ and Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC medicine. 2011; 9:33.
4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD. Metformin and reduced risk of cancer in diabetic patients. Bmj. 2005; 330:1304-1305.
5. Gong J, Kelekar G, Shen J, Shen J, Kaur S and Mita M. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Targeted oncology. 2016; 11:447-467.
6. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer research. 2009; 69:6539-6545.
7. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27:3576-3586.
8. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer research. 2007; 67:6745-6752.
9. Algire C, Zakikhani M, Blouin MJ, Shuai JH and Pollak M. Metformin attenuates the stimulatory effect of a highenergy diet on in vivo LLC1 carcinoma growth. Endocrinerelated cancer. 2008; 15:833-839.
10. Yi G, He Z, Zhou X, Xian L, Yuan T, Jia X, Hong J, He L and Liu J. Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. International journal of oncology. 2013; 43:1503-1510.
11. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. The Journal of biological chemistry. 2000; 275:223-228.
12. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA and Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:3329-3335.
13. Inoki K, Zhu T and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003; 115:577-590.
14. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005; 24:1477-1480.
15. Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, Aimone P, Fretault N, Dharan B, Tavorath R and Hirawat S. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and therapy. 2016; 9:203-210.
16. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular cell. 2008; 30:214-226.
17. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC and Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell metabolism. 2010; 11:390-401.
18. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S and Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer research. 2011; 71:4366-4372.
19. Zhu M, Zhang Q, Wang X, Kang L, Yang Y, Liu Y, Yang L, Li J, Yang L, Liu J, Li Y, Zu L, Shen Y and Qi Z. Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway. Oncotarget. 2016; doi: 10.18632/oncotarget.12391.
20. Yang L, Yang L, Tian W, Li J, Liu J, Zhu M, Zhang Y, Yang Y, Liu F, Zhang Q, Liu Q, Shen Y and Qi Z. Resveratrol plays dual roles in pancreatic cancer cells. Journal of cancer research and clinical oncology. 2014; 140:749-755.
21. Dowling RJ, Niraula S, Stambolic V and Goodwin PJ. Metformin in cancer: translational challenges. Journal of molecular endocrinology. 2012; 48:R31-43.
22. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E and Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:1809-1814.
23. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG and Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009; 460:103-107.
24. Prlic M, Williams MA and Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Current opinion in immunology. 2007; 19:315-319.
25. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.
26. Amelio I, Cutruzzola F, Antonov A, Agostini M and Melino G. Serine and glycine metabolism in cancer. Trends in biochemical sciences. 2014; 39:191-198.
27. Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, St Pierre J and Pollak MN. Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. PloS one. 2012; 7:e49513.
28. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC and Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:10574-10579.
29. Akinlade KS, Agbebaku SO, Rahamon SK and Balogun WO. Vitamin B12 Levels In Patients with Type 2 Diabetes Mellitus on Metformin. Annals of Ibadan postgraduate medicine. 2015; 13:79-83.
30. Fogelman Y, Kitai E, Blumberg G, Golan-Cohen A, Rapoport M and Carmeli E. Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested? Aging clinical and experimental research. 2016; doi: 10.1007/s40520-016-0546-1.
31. Garcia A and Tisman G. Metformin, B(12), and enhanced breast cancer response to chemotherapy. Journal of clinical oncology. 2010; 28:e19; author reply e20.
32. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cocheme HM, Noori T, Weinkove D, Schuster E, Greene ND and Gems D. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013; 153:228-239.
33. Astagimath MN and Rao SB. Dietary restriction (DR) and its advantages. Indian journal of clinical biochemistry. 2004; 19:1-5.
34. Li S, Swanson SK, Gogol M, Florens L, Washburn MP, Workman JL and Suganuma T. Serine and SAM Responsive Complex SESAME Regulates Histone Modification Crosstalk by Sensing Cellular Metabolism. Molecular cell. 2015; 60:408-421.
35. Yu X and Li S. Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene. 2016; doi: 10.1038/onc.2016.410.
36. Li S, Kong L, Yu X and Zheng Y. Host-virus interactions: from the perspectives of epigenetics. Reviews in medical virology. 2014; 24:223-241.
37. Du Y, Zheng H, Wang J, Ren Y, Li M, Gong C, Xu F and Yang C. Metformin inhibits histone H2B monoubiquitination and downstream gene transcription in human breast cancer cells. Oncology letters. 2014; 8:809-812.
38. Gao Z and Xu CW. Glucose metabolism induces monoubiquitination of histone H2B in mammalian cells. Biochemical and biophysical research communications. 2011; 404:428-433.
39. Li S and Shogren-Knaak MA. Cross-talk between histone H3 tails produces cooperative nucleosome acetylation. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:18243-18248.
40. Li S and Shogren-Knaak MA. The Gcn5 bromodomain of the SAGA complex facilitates cooperative and crosstail acetylation of nucleosomes. The Journal of biological chemistry. 2009; 284:9411-9417.
41. Zhang E, Guo Q, Gao H, Xu R, Teng S and Wu Y. Metformin and Resveratrol Inhibited High Glucose-Induced Metabolic Memory of Endothelial Senescence through SIRT1/p300/p53/p21 Pathway. PloS one. 2015; 10:e0143814.
42. Khan S and Jena G. Sodium butyrate reduces insulinresistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. Chemicobiological interactions. 2016; 254:124-134.
43. Banerjee P, Surendran H, Chowdhury DR, Prabhakar K and Pal R. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter. Journal of molecular medicine. 2016.
44. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H and Huang Y. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015; 34:3076-3084.
45. Boukouris AE, Zervopoulos SD and Michelakis ED. Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription. Trends in biochemical sciences. 2016.
46. Ishikawa K, Tsunekawa S, Ikeniwa M, Izumoto T, Iida A, Ogata H, Uenishi E, Seino Y, Ozaki N, Sugimura Y, Hamada Y, Kuroda A, Shinjo K, Kondo Y and Oiso Y. Long-term pancreatic beta cell exposure to high levels of glucose but not palmitate induces DNA methylation within the insulin gene promoter and represses transcriptional activity. PloS one. 2015; 10:e0115350.
47. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D and Trajkovic V. In vitro and in vivo anti-melanoma action of metformin. European journal of pharmacology. 2011; 668:373-382.
48. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecologic oncology. 2010; 116:92-98.
49. Guimaraes TA, Farias LC, Santos ES, de Carvalho Fraga CA, Orsini LA, de Freitas Teles L, Feltenberger JD, de Jesus SF, de Souza MG, Santos SH, de Paula AM, Gomez RS and Guimaraes AL. Metformin increases PDH and suppresses HIF-1alpha under hypoxic conditions and induces cell death in oral squamous cell carcinoma. Oncotarget. 2016; doi: 10.18632/oncotarget.10842.
50. Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ, Han X, Wang HY, Sun GP and Liu H. Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Experimental and therapeutic medicine. 2016; 11:1700-1706.
51. Li P, Zhao M, Parris AB, Feng X and Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochemical and biophysical research communications. 2015; 464:1267-1274.
52. Sun Y, Tao C, Huang X, He H, Shi H, Zhang Q and Wu H. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway. OncoTargets and therapy. 2016; 9:2845-2853.
53. Golias T, Papandreou I, Sun R, Kumar B, Brown NV, Swanson BJ, Pai R, Jaitin D, Le QT, Teknos TN and Denko NC. Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Scientific reports. 2016; 6:31146.
54. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A, Yan W, Logan SK and Li X. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34:2823-2832.
55. Noren Hooten N, Martin-Montalvo A, Dluzen DF, Zhang Y, Bernier M, Zonderman AB, Becker KG, Gorospe M, de Cabo R and Evans MK. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging cell. 2016; 15:572-581.
56. Hirsch HA, Iliopoulos D and Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:972-977.
57. Duo J, Ma Y, Wang G, Han X and Zhang C. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line. DNA and cell biology. 2013; 32:156-164.
58. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer research. 2009; 69:7507-7511.
59. Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S and Thompson AM. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. Breast cancer research and treatment. 2015; 150:149-155.
60. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S and Menendez JA. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Annals of oncology. 2010; 21:187-189.